Wybrane najnowsze publikacje naszych autorów

• Saini K., Koopman M., Martins-Branco D., Bossi P., Braendegaard Winther S., Brahmi M., Braña I., Calvo E., Castelo-Branco L., Colombo I., de Azambuja E., De Ruysscher D., Dienstmann R., Dingemans A., Ekholm M., Gallois C., Golfinopoulos V., Grande E., Halabi S., Le Rhun E., Le Saux O., Leighl N., Lonardi S., Lorenzen S., Lorusso D., Minniti G., Mountzios G., Oldenburg J., Oosting S., Osterlund P., Perez-Gracia J., Pellat A., Piperno-Neumann S., Plummer R., Porta C., Punie K., Ray-Coquard I., Remon J., Ruhlmann C., Rutkowski P., Siu L., Stacchiotti S., Suarez C., Suijkerbuijk K., Taieb J., Trapani D., Valachis A., van Laarhoven H., Vogel A., Zer A., Pentheroudakis G., Delaloge S., Twelves C.: ESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours,Annals of Oncology. 2026; 37 (5):608-623. DOI: 10.1016/j.annonc.2026.02.008
• Schlaak M., Cimminiello C., Pigozzo J., Lee J., Grabbe S., Rutkowski P., Mackiewicz J., Tsai K. K., Ascierto P. A., Mandalà M., Carnevale-Schianca F., Haferkamp S., Atkinson V., Hassel J. C., Sandhu S., Sharfman W., Dean E., Noor U., Iyer S., Rabbie R., Ribas A.: MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition. Clinical Cancer Research. 2026. DOI: 10.1158/1078-0432.CCR-25-3951
• Roohani S., Spałek M. J., Aggerholm-Pedersen N., Eckert F., Ashleigh Guadagnolo B., Kirsch D. G., Péchoux C. L., Miah A. B., Salerno K. E., Sangalli C., Simões R., Walter R., Wiltink L. M., Zaidi S., Timmermann B., Haas R. L.: ESTRO clinical practice guideline on radiotherapy for adult soft tissue sarcoma of the extremities and trunk wall - Endorsed by ASTRO. Radiotherapy & Oncology. 2026 Apr 16:111535. . DOI: 10.1016/j.radonc.2026.111535
• Hofland J., Grana C., Weickert M., Moore A., Shah T., Prakash V., Kolasińska-Ćwikła A., de Herder W., Spada F., Xu L., Fite R., Wu Y., Ćwikła J.: The effect of LysaKare infusion on serum potassium levels in patients with gastroenteropancreatic neuroendocrine tumours eligible for treatment with [177Lu]Lu-DOTA-TATE: A post-authorisation safety study. Journal of Neuroendocrinology. 2026;38(4):e70172. DOI: 10.1111/jne.70172
• Czarnecka A., Błoński P., Chmiel P., Zdzienicki M., Szumera-Ciećkiewicz A., Pieńkowski A., Teterycz P., Spałek M., Świtaj T., Falkowski S., Wągrodzki M., Rutkowski P.:Long-term efficacy of radical treatment of patients with clear cell sarcoma. European Journal of Surgical Oncology. 2026;52(5):111485. DOI: 10.1016/j.ejso.2026.111485